Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
The Medical Basis of Psychiatry / / edited by S. Hossein Fatemi, Paula J. Clayton
| The Medical Basis of Psychiatry / / edited by S. Hossein Fatemi, Paula J. Clayton |
| Edizione | [4th ed. 2016.] |
| Pubbl/distr/stampa | New York, NY : , : Springer New York : , : Imprint : Springer, , 2016 |
| Descrizione fisica | 1 online resource (1062 p.) |
| Disciplina | 610 |
| Soggetto topico |
Psychiatry
Neurosciences Neurology Internal medicine Neurology Internal Medicine |
| ISBN | 1-4939-2528-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The Mental Status Examination -- Syndromes of Brain Dysfunction Presenting with Cognitive Impairment or Behavioral Disturbance: Delirium, Dementia, and Mental Disorders Due to Another Medical Condition -- The Amnestic Syndrome -- Bipolar Illness -- Major Depressive Disorder -- Schizophrenia -- Schizoaffective and Schizophreniform Disorders -- Delusional Disorders -- Anxiety Disorders -- Obsessive Compulsive Disorder -- Somatizing and Dissociative Disorders -- Anorexia Nervosa and Bulimia Nervosa -- Antisocial Personality Disorder -- Alcoholism -- Drug Addiction -- Sexual Disorders: Dysfunction, Gender Identity and Paraphilias -- Other Psychiatric Syndromes: Adjustment Disorder, Factitious Disorder, Illicit Steroid Abuse, Cultural Syndromes -- ADHD and the Disruptive Behavior Disorders -- Mood Disorders in Children and Adolescents -- Autism Spectrum Disorder -- Childhood Anxiety Disorders and Obsessive-Compulsive Disorder -- Schizophrenia in Children and Adolescents -- Mood Disturbances -- Anxiety Symptoms -- Thought Disorder -- From Phenomenology to Strong Biologism and Epigenetics in Psychiatry -- Catatonia in Psychiatric Illnesses -- Personality Disorders -- Genetics of Psychiatric Disorders -- Novel Targets for Drug Treatment in Psychiatry -- Use of Laboratory in Psychiatry -- Epidemiology of Psychiatric Illness -- Suicide and Attempted Suicide -- Clinical Psychopharmacology -- Cognitive and Behavioral Therapies -- Forensic Psychiatry -- Sleep Disorders -- Neuromodulation in Psychiatry -- Rating Scales for Psychiatric Disorders -- Neuroimaging in Psychiatry -- Electroconvulsive Therapy: Indications, Use and Adverse Effects -- Profiles in History of Neuroscience and Psychiatry -- Normal Laboratory Values and Drug Therapeutic and Toxic Ranges. |
| Record Nr. | UNINA-9910254517503321 |
| New York, NY : , : Springer New York : , : Imprint : Springer, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Molecular Basis of Autism / / edited by S. Hossein Fatemi
| The Molecular Basis of Autism / / edited by S. Hossein Fatemi |
| Edizione | [1st ed. 2015.] |
| Pubbl/distr/stampa | New York, NY : , : Springer New York : , : Imprint : Springer, , 2015 |
| Descrizione fisica | 1 online resource (438 p.) |
| Disciplina | 155 |
| Collana | Contemporary Clinical Neuroscience |
| Soggetto topico |
Neurosciences
Psychiatry Developmental psychology Developmental Psychology |
| ISBN | 1-4939-2190-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- A Brief History of Autism -- Autism Spectrum Disorder: Diagnostic Considerations -- Epidemiologic Features of Autism Spectrum Disorders -- Genetics of Autism Spectrum Disorders: The Opportunity and Challenge in the Genetics Clinic -- Epigenetic Regulation in Autism -- Immunology of Autism -- Neuroimaging in Autism Spectrum Disorders -- The Neuropathology of Autism -- Pharmacology of ASD Spectrum Disorder -- Behavioral Therapies -- Autism and Dopamine -- Autism and Glutamate -- Serotonin in Autism Spectrum Disorder: Insights From Human Studies and Animal Models -- Oxytocin and Vasopressin in Autism and Genetic Syndromes -- Molecular basis of cholinergic changes in autistic spectrum disorders and relevance for treatment interventions -- Reelin, GABA, FMRP, and Autism -- The Role of Neurexins and Neuroligins in Autism -- Neurotrophins, their receptors and autism: ligand vs. receptor abnormalities -- Cognition, Motor Control and Other Aspects of Autism: A Pragmatic Review -- Increased vulnerability to oxidative stress and mitochondrial dysfunction in autism -- Index. |
| Record Nr. | UNINA-9910298271803321 |
| New York, NY : , : Springer New York : , : Imprint : Springer, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Psychopharmacology [[electronic resource] ] : an introduction / / René Spiegel ; with contributions by S. Hossein Fatemi ... [et al.]
| Psychopharmacology [[electronic resource] ] : an introduction / / René Spiegel ; with contributions by S. Hossein Fatemi ... [et al.] |
| Autore | Spiegel René |
| Edizione | [4th ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 |
| Descrizione fisica | 1 online resource (424 p.) |
| Disciplina |
615.78
615/.78 |
| Altri autori (Persone) | FatemiS. Hossein |
| Soggetto topico | Psychopharmacology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
9786610101603
0-470-86947-X 1-280-10160-1 0-470-86946-1 0-470-34553-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Psychopharmacology; Contents; Preface; Preface to Third Edition; Preface to Second Edition; Foreword (by Herbert Meltzer); 1 Modern Psychopharmaceuticals (Revision by Hossein Fatemi); 1.1 Definition and classification; 1.2 Antipsychotics; 1.2.1 Clinical actions and uses; 1.2.2 The best-known products; 1.2.3 Differences between different products; 1.2.4 Side effects ('adverse effects') of antipsychotics; 1.2.5 Neuroleptics and tardive dyskinesias: unanswered questions; 1.3 Antidepressants; 1.3.1 Clinical actions and uses; 1.3.2 The best-known products; 1.3.3 How effective are antidepressants?
1.3.4 Side effects of antidepressants1.4 Mood stabilizers; 1.4.1 Clinical actions and uses; 1.4.2 Side effects of mood stabilizers; 1.5 Anxiolytics and hypnotics; 1.5.1 Clinical actions and uses; 1.5.2 The best-known products; 1.5.3 Anxiolytics or psychotherapy?; 1.5.4 Side effects of anxiolytics; 1.5.5 Dependency on benzodiazepines; 1.5.6 Alternatives to benzodiazepines; 1.6 Psychostimulants; 1.6.1 Actions and uses of psychostimulants; 1.6.2 The best-known psychostimulants; 1.7 Nootropics and antidementia drugs; 1.8 Concluding comment; 2 The History of Psychopharmacology; 2.1 Introduction 2.2 Psychopharmacology in the ancient world and Middle Ages2.2.1 The most important substances; 2.2.2 Psychopharmaceuticals and the history of psychiatry; 2.3 The modern age: psychopharmacology before chlorpromazine; 2.4 The discovery of modern psychopharmaceuticals; 2.4.1 Chlorpromazine; 2.4.2 Antidepressants; 2.4.3 Tranquillizers; 2.5 Discussion: how were modern psychopharmaceuticals discovered?; 2.5.1 Chance discovery; 2.5.2 Serendipity and spirit of the age (Zeitgeist); 2.5.3 Quantitative aspects; 2.6 The past 20 years; 2.6.1 Atypical antipsychotic drugs; 2.6.2 New antidepressants: SSRIs 2.6.3 Drugs to treat Alzheimer's disease (AD)2.7 Concluding remarks; 3 Effects of Psychotropic Medication on Healthy Subjects; 3.1 Introduction; 3.2 Studies conducted by Emil Kraepelin; 3.3 Assessment methods used in drug experiments on healthy volunteers; 3.3.1 Methods for recording subjective drug effects; 3.3.2 Methods for recording behavioral drug effects; 3.3.3 Neurophysiological parameters; 3.4 Findings in drug experiments on healthy volunteers; 3.4.1 Antipsychotic drugs; 3.4.2 Antidepressant drugs; 3.4.3 Anxiolytic and hypnotic drugs; 3.4.4 Psychostimulant drugs 3.4.5 Nootropics and antidementia drugs3.5 Discussion; 3.5.1 Differential drug effects; 3.5.2 Sensitivity of the assessment methods used in pharmacopsychology; 3.5.3 Understanding and predicting clinical drug effects; 3.5.4 Theory-orientated issues; 3.6 Conclusions; 4 Preclinical Research in Psychopharmacology (by Conrad Gentsch); 4.1 Introduction; 4.2 The target; 4.2.1 The nervous system; 4.2.2 Neurons; 4.2.3 Synapses; 4.2.4 Receptors; 4.2.5 Ligands; 4.2.6 Interaction between the ligand and receptor; 4.2.7 Neurotransmitters 4.3 Hypotheses relating to the mode of action of psychopharmaceuticals |
| Record Nr. | UNINA-9910144731203321 |
Spiegel René
|
||
| Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Psychopharmacology [[electronic resource] ] : an introduction / / René Spiegel ; with contributions by S. Hossein Fatemi ... [et al.]
| Psychopharmacology [[electronic resource] ] : an introduction / / René Spiegel ; with contributions by S. Hossein Fatemi ... [et al.] |
| Autore | Spiegel René |
| Edizione | [4th ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 |
| Descrizione fisica | 1 online resource (424 p.) |
| Disciplina |
615.78
615/.78 |
| Altri autori (Persone) | FatemiS. Hossein |
| Soggetto topico | Psychopharmacology |
| ISBN |
9786610101603
0-470-86947-X 1-280-10160-1 0-470-86946-1 0-470-34553-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Psychopharmacology; Contents; Preface; Preface to Third Edition; Preface to Second Edition; Foreword (by Herbert Meltzer); 1 Modern Psychopharmaceuticals (Revision by Hossein Fatemi); 1.1 Definition and classification; 1.2 Antipsychotics; 1.2.1 Clinical actions and uses; 1.2.2 The best-known products; 1.2.3 Differences between different products; 1.2.4 Side effects ('adverse effects') of antipsychotics; 1.2.5 Neuroleptics and tardive dyskinesias: unanswered questions; 1.3 Antidepressants; 1.3.1 Clinical actions and uses; 1.3.2 The best-known products; 1.3.3 How effective are antidepressants?
1.3.4 Side effects of antidepressants1.4 Mood stabilizers; 1.4.1 Clinical actions and uses; 1.4.2 Side effects of mood stabilizers; 1.5 Anxiolytics and hypnotics; 1.5.1 Clinical actions and uses; 1.5.2 The best-known products; 1.5.3 Anxiolytics or psychotherapy?; 1.5.4 Side effects of anxiolytics; 1.5.5 Dependency on benzodiazepines; 1.5.6 Alternatives to benzodiazepines; 1.6 Psychostimulants; 1.6.1 Actions and uses of psychostimulants; 1.6.2 The best-known psychostimulants; 1.7 Nootropics and antidementia drugs; 1.8 Concluding comment; 2 The History of Psychopharmacology; 2.1 Introduction 2.2 Psychopharmacology in the ancient world and Middle Ages2.2.1 The most important substances; 2.2.2 Psychopharmaceuticals and the history of psychiatry; 2.3 The modern age: psychopharmacology before chlorpromazine; 2.4 The discovery of modern psychopharmaceuticals; 2.4.1 Chlorpromazine; 2.4.2 Antidepressants; 2.4.3 Tranquillizers; 2.5 Discussion: how were modern psychopharmaceuticals discovered?; 2.5.1 Chance discovery; 2.5.2 Serendipity and spirit of the age (Zeitgeist); 2.5.3 Quantitative aspects; 2.6 The past 20 years; 2.6.1 Atypical antipsychotic drugs; 2.6.2 New antidepressants: SSRIs 2.6.3 Drugs to treat Alzheimer's disease (AD)2.7 Concluding remarks; 3 Effects of Psychotropic Medication on Healthy Subjects; 3.1 Introduction; 3.2 Studies conducted by Emil Kraepelin; 3.3 Assessment methods used in drug experiments on healthy volunteers; 3.3.1 Methods for recording subjective drug effects; 3.3.2 Methods for recording behavioral drug effects; 3.3.3 Neurophysiological parameters; 3.4 Findings in drug experiments on healthy volunteers; 3.4.1 Antipsychotic drugs; 3.4.2 Antidepressant drugs; 3.4.3 Anxiolytic and hypnotic drugs; 3.4.4 Psychostimulant drugs 3.4.5 Nootropics and antidementia drugs3.5 Discussion; 3.5.1 Differential drug effects; 3.5.2 Sensitivity of the assessment methods used in pharmacopsychology; 3.5.3 Understanding and predicting clinical drug effects; 3.5.4 Theory-orientated issues; 3.6 Conclusions; 4 Preclinical Research in Psychopharmacology (by Conrad Gentsch); 4.1 Introduction; 4.2 The target; 4.2.1 The nervous system; 4.2.2 Neurons; 4.2.3 Synapses; 4.2.4 Receptors; 4.2.5 Ligands; 4.2.6 Interaction between the ligand and receptor; 4.2.7 Neurotransmitters 4.3 Hypotheses relating to the mode of action of psychopharmaceuticals |
| Record Nr. | UNINA-9910830009303321 |
|
Spiegel René
|
||
| Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Psychopharmacology : an introduction / / Rene Spiegel ; with contributions by S. Hossein Fatemi ... [et al.]
| Psychopharmacology : an introduction / / Rene Spiegel ; with contributions by S. Hossein Fatemi ... [et al.] |
| Autore | Spiegel Rene |
| Edizione | [4th ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 |
| Descrizione fisica | 1 online resource (424 p.) |
| Disciplina | 615/.78 |
| Altri autori (Persone) | FatemiS. Hossein |
| Soggetto topico | Psychopharmacology |
| ISBN |
9786610101603
0-470-86947-X 1-280-10160-1 0-470-86946-1 0-470-34553-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Psychopharmacology; Contents; Preface; Preface to Third Edition; Preface to Second Edition; Foreword (by Herbert Meltzer); 1 Modern Psychopharmaceuticals (Revision by Hossein Fatemi); 1.1 Definition and classification; 1.2 Antipsychotics; 1.2.1 Clinical actions and uses; 1.2.2 The best-known products; 1.2.3 Differences between different products; 1.2.4 Side effects ('adverse effects') of antipsychotics; 1.2.5 Neuroleptics and tardive dyskinesias: unanswered questions; 1.3 Antidepressants; 1.3.1 Clinical actions and uses; 1.3.2 The best-known products; 1.3.3 How effective are antidepressants?
1.3.4 Side effects of antidepressants1.4 Mood stabilizers; 1.4.1 Clinical actions and uses; 1.4.2 Side effects of mood stabilizers; 1.5 Anxiolytics and hypnotics; 1.5.1 Clinical actions and uses; 1.5.2 The best-known products; 1.5.3 Anxiolytics or psychotherapy?; 1.5.4 Side effects of anxiolytics; 1.5.5 Dependency on benzodiazepines; 1.5.6 Alternatives to benzodiazepines; 1.6 Psychostimulants; 1.6.1 Actions and uses of psychostimulants; 1.6.2 The best-known psychostimulants; 1.7 Nootropics and antidementia drugs; 1.8 Concluding comment; 2 The History of Psychopharmacology; 2.1 Introduction 2.2 Psychopharmacology in the ancient world and Middle Ages2.2.1 The most important substances; 2.2.2 Psychopharmaceuticals and the history of psychiatry; 2.3 The modern age: psychopharmacology before chlorpromazine; 2.4 The discovery of modern psychopharmaceuticals; 2.4.1 Chlorpromazine; 2.4.2 Antidepressants; 2.4.3 Tranquillizers; 2.5 Discussion: how were modern psychopharmaceuticals discovered?; 2.5.1 Chance discovery; 2.5.2 Serendipity and spirit of the age (Zeitgeist); 2.5.3 Quantitative aspects; 2.6 The past 20 years; 2.6.1 Atypical antipsychotic drugs; 2.6.2 New antidepressants: SSRIs 2.6.3 Drugs to treat Alzheimer's disease (AD)2.7 Concluding remarks; 3 Effects of Psychotropic Medication on Healthy Subjects; 3.1 Introduction; 3.2 Studies conducted by Emil Kraepelin; 3.3 Assessment methods used in drug experiments on healthy volunteers; 3.3.1 Methods for recording subjective drug effects; 3.3.2 Methods for recording behavioral drug effects; 3.3.3 Neurophysiological parameters; 3.4 Findings in drug experiments on healthy volunteers; 3.4.1 Antipsychotic drugs; 3.4.2 Antidepressant drugs; 3.4.3 Anxiolytic and hypnotic drugs; 3.4.4 Psychostimulant drugs 3.4.5 Nootropics and antidementia drugs3.5 Discussion; 3.5.1 Differential drug effects; 3.5.2 Sensitivity of the assessment methods used in pharmacopsychology; 3.5.3 Understanding and predicting clinical drug effects; 3.5.4 Theory-orientated issues; 3.6 Conclusions; 4 Preclinical Research in Psychopharmacology (by Conrad Gentsch); 4.1 Introduction; 4.2 The target; 4.2.1 The nervous system; 4.2.2 Neurons; 4.2.3 Synapses; 4.2.4 Receptors; 4.2.5 Ligands; 4.2.6 Interaction between the ligand and receptor; 4.2.7 Neurotransmitters 4.3 Hypotheses relating to the mode of action of psychopharmaceuticals |
| Record Nr. | UNINA-9910876503703321 |
|
Spiegel Rene
|
||
| Chichester, West Sussex, England ; ; Hoboken, NJ, : John Wiley & Sons, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||